Some heartening news for breast cancer patients: a recent study has shown that Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, can increase survival of women with advanced breast cancer by nearly 16 months. When cancer reaches the advanced stage, it becomes metastasis. This means it has started spreading to the other parts of the body. In such cases, most cancer drugs are only able to prolong survival for a few months. The results for this Perjeta study, involving 808 patients worldwide, was thus considered a groundbreaking one.
To learn more about the study, visit http://www.roche.com/investors/ir_update/inv-update-2014-09-28.htm